TrialJournal of clinical psychopharmacology2014

A short-term, multicenter, placebo-controlled, randomized withdrawal study of a metabotropic glutamate 2/3 receptor agonist using an electronic patient-reported outcome device in patients with schizophrenia.

Virginia L Stauffer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.